Company profile
Onconetix, Inc.
NASDAQ: ONCO · Healthcare · Biotechnology
#886 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
24DFH 34DQ 12GM —SS 17
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, return on assets · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$735.2k
Rev growth YoY (TTM)
-61.8%
Net income (FY)
-$14.0M
Employees
2
as of 2026-08-27
Market cap
$2.3M
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$815.4k$815.4k2025
Net income-$14.0M-$14.0M2025
Operating income-$17.9M-$17.9M2025
Total assets$24.9M$24.9M2025
Liabilities$9.2M$9.2M2025
Equity$15.8M$15.8M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
European Union100%
The read
What is Onconetix, Inc.’s revenue?
Onconetix, Inc. booked $815.4k in FY2025 revenue, contracting 68% year over year — slower than 86% of Healthcare companies we track, at a -1721.0% net margin.
Peers · Healthcare
Advantis Corp.——Imagenetix, Inc.——Catheter Precision, Inc.39DHyperion DeFi, Inc.35DHelix BioMedix, Inc.56CImageneBio Inc48DNeighbors
Hamilton →Key facts
CEODavid Allan White
SectorHealthcare
IndustryBiotechnology
HeadquartersCincinnati, OH
ExchangeNASDAQ: ONCO
Employees2
IPO date2022-02-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.